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Following surgical removal of the canine pancreas, Joseph von Mering and Oskar 
Minkowski were the first to link the pancreas with diabetes (1). This observation led to 
the successful treatment of diabetic patients some 30 years later using purified pancreatic 
extracts, then to the identification and application of subcutaneous insulin delivery, as 
well as more recent islet transplantation therapies (2). Despite these life-saving advances 
diabetes is still a global healthcare problem. However, there remains much to learn about 
the mechanisms involved in glucose homeostasis. Insulin receptor signaling is the central 
molecular pathway and remains the subject of intense research activity. Mouse knockout 
models have played a pivotal role in bridging the gap between our understanding of the 
relevant molecular mechanisms and glucose homeostasis in the whole animal (3-5).  
 
In this issue, Zhang et al (6) report on the pancreas-specific disruption of the Grb10 
signaling adaptor protein gene. This builds on a long tradition of mouse knockout 
experiments targeting components of the insulin signaling pathway. Seminally, germline 
or “global” disruption of the insulin receptor gene (Insr) revealed a subtle effect of Insr 
signaling on fetal growth (7) as well as perinatal lethality due to acute diabetic 
ketoacidosis (8; 9). The physiological effects of gene disruption can be difficult to 
interpret when they involve such a severe phenotype and/or when signaling is altered 
within multiple insulin-sensitive tissues. To circumvent these problems “conditional” or 
tissue-specific mouse knockouts can be generated using Cre-lox technology, an approach 
used to great effect within the glucose homeostasis field. In a series of elegant 
experiments the effects of Insr ablation have been analysed separately in several tissues, 
including, skeletal muscle, white adipose, liver, brain and pancreas (reviewed in(3-5)). 
This work revealed roles for Insr signaling in non-canonical insulin-responsive tissues, 
such as liver, brain and endocrine pancreas that were more prominent than had previously 
been appreciated (4). A number of genes acting downstream of the Insr have also been 
the subject of mouse knockout experiments. Broadly speaking, knockouts resulting in 
impaired signaling, such as those for Irs-1, Irs-2 and Akt2, were associated with insulin 
resistance or diabetes, whereas knockouts that disrupted an inhibitor of insulin signaling 
(e.g. PTP1B) led to increased insulin sensitivity. These experiments also revealed myriad 
subtleties, for instance, due to redundancies between related factors and to the relative 
importance of individual factors in specific tissues (3-5).   
 
The Grb10 signaling adaptor functions to inhibit signaling through receptor tyrosine 
kinases including the Insr and insulin-like growth factor type 1 receptor (Igf1r) (10). 
Grb10 germline knockout mice have elevated Insr/Igf1r downstream signaling, at least in 
skeletal muscle and white adipose tissue (WAT), without an increase in circulating 
insulin levels, and have an enhanced ability to clear a glucose load from the circulation 
(11-13) (Table 1). Expression of Grb10 is widespread during fetal development but more 
restricted post-natally, including in both canonical (muscle and WAT) and non-canonical 
(pancreas and brain) insulin-responsive tissues (11; 12). Grb10 is known to inhibit both 
fetal and placental growth, such that Grb10 knockout mice are at birth approximately 
30% heavier than their wild type sibs (14). In adulthood Grb10 knockout mice have 
increased muscle mass and reduced adipose compared to wild types (11; 12; 15). This 
“anti-diabetic” phenotype, of lean body proportions with an enhanced ability to clear 
blood glucose, is very interesting but needs to be better understood.  
 In the paper by Zhang et al (6), the first report of a conditional Grb10 knockout, Grb10 
was abolished in pancreas by crossing a “floxed” Grb10 allele with transgenic mice that 
express Cre-recombinase under the control of a pancreas-specific Pdx1 gene promoter. 
Global Grb10 knockout resulted in significantly increased growth of many tissues, 
including pancreas (11-15). Zhang et al. (6) confirm that Grb10 is expressed in 
pancreatic islets of adult mice and show that pancreas-specific Grb10 knockout resulted 
in a substantial increase in pancreas tissue weight. This observation is consistent with the 
established role for Grb10 as an inhibitor of tissue growth (14; 16) and indicates that 
Grb10 participates in a local growth control mechanism, consistent with its intracellular 
signaling function. More work will be required to uncover the relative importance of 
Grb10 in regulating pancreas growth during development, versus tissue maintenance in 
adulthood. Under control of the Pdx1 promoter, Cre recombinase is expressed from the 
earliest stages of pancreas development (17), resulting in deletion of the Grb10 floxed 
allele in both exocrine and endocrine tissue. Expression of Grb10 is not readily detected 
in exocrine pancreas (6; 11). However, in a separate study, knock-down of Grb10 levels 
in adult mouse pancreas using viral delivery of a short hairpin RNA targeting Grb10 
resulted in increased apoptosis of both endocrine and exocrine tissue (18), supporting a 
role for Grb10 in promoting cell survival in both compartments. Disrepancies between 
the two studies (6; 18) will need to be resolved, but could be due to differences in the 
techniques used and the timing of Grb10 knockout or knock-down. 
 
Importantly, Zhang et al. (6) show that loss of pancreatic Grb10 resulted in increased 
beta-cell mass, with an associated increase in the number of insulin secretory granules, 
insulin secretion and improved glucose tolerance, but without a significant change in 
insulin tolerance. These favourable changes in pancreatic beta-cell physiology were 
replicated in mice challenged with a high fat diet and, moreover, pancreas-specific Grb10 
knockout ameliorated the effects of streptozotocin-induced diabetes. This fuels the 
suggestion that inhibition of Grb10 might offer a means of increasing beta-cell mass in 
type 1 and type 2 diabetes. In this context, it is interesting to compare the outcomes of 
pancreas-specific with global Grb10 knockouts (Table 1). Mice lacking Grb10 in all 
tissues had increased lean tissue mass, with no significant change in circulating insulin 
levels, despite having an enlarged pancreas, and exhibited improvements in both glucose 
tolerance and insulin sensitivity (11; 12). Collectively, the global and tissue-specific 
knockout experiments indicate a role for Grb10 in coordinating endocrine pancreas 
function with that of the canonical insulin-sensitive tissues, suggesting there may be 
additive therapeutic benefits from targeting Grb10 function at both sites. However, if 
therapeutic molecules are to be developed then a greater understanding is needed of the 
signaling pathways that Grb10 acts on in vivo. Zhang et al. (6) provide evidence of 
increased Insr/Igf1r signaling in islets lacking Grb10 expression but also point out that 
this is not necessarily the cause of the increased beta-cell mass. The recently established 
link between Grb10 and mTOR signaling is a promising advance (19; 20) and data 
reported by Zhang et al. (6) showing increased mTOR signaling in Grb10 knockout islets 
is an early indication that the link has physiological significance. 
 
The conditional Grb10 knockout mice have illuminated the pancreatic role of Grb10 (6) 
and will undoubtedly continue to aid in unraveling the intricacies of Grb10 signaling 
function, allowing key questions to be addressed, including: What are the tissue-specific 
roles of Grb10 in the regulation of Insr signaling? What are the relative contributions of 
altered signaling versus body proportions to the physiological changes seen in Grb10 
knockout mice? 
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  Global Grb10 knockout Pancreas-specific Grb10 
knockout 
Body weight ↑  
Food intake   
Adipose ↓  
Skeletal muscle ↑ n.d. 
Pancreas weight ↑ ↑ 
Beta-cell mass n.d. ↑ 
Insulin levels  ↑ 
Insulin sensitivity ↑ n.d. 
Glucose clearance ↑ ↑ 
Insr/Igf1r signaling in 
skeletal muscle and WAT 
↑ n.d. 
Insr/Igf1r signaling in islets n.d. ↑ 
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Table 1. Phenotypic comparison of adult mice with either global or pancreas-
specific Grb10 knockout alleles illustrates differences in body composition, insulin 
signaling and glucose-regulated metabolism, relative to wild type controls. Pancreas 
weight is increased in both models. Global knockouts have insulin levels appropriate for 
their body weight, and enhanced glucose clearance is associated with increased insulin 
sensitivity and enhanced Insr/Igf1r signaling in peripheral tissues. Pancreas-specific 
knockouts also exhibit enhanced glucose clearance, but in this case associated with 
increased insulin levels and secretion. Key: , no change; ↑, increased ↓, decreased; n.d., 
not determined.  
 
 
